Published in:
British Journal of Pharmacology, 173 (2016) 17, Seite 2622-2632
Language:
English
DOI:
10.1111/bph.13541
ISSN:
0007-1188;
1476-5381
Origination:
Footnote:
Description:
Background and PurposeObesity is one of the most prevalent chronic diseases worldwide, and dysregulated adipocyte function plays an important role in obesity‐associated metabolic disorder. The level of plasma plasminogen activator inhibitor‐1 (PAI‐1) is increased in obese subjects, and PAI‐1 null mice show improved insulin sensitivity when subjected to high‐fat and high‐sucrose diet‐induced metabolic stress, suggesting that a best‐in‐class PAI‐1 inhibitor may become a novel therapeutic agent for obesity‐associated metabolic syndrome. TM5441 is a novel orally active PAI‐1 inhibitor that does not cause bleeding episodes. Hence, in the present study we examined the preventive effect of TM5441 on high‐fat diet (HFD)‐induced adipocyte dysfunction.Experimental ApproachTen‐week‐old C57BL/6J mice were fed a normal diet (18% of total calories from fat) or HFD (60% of total calories from fat) for 10 weeks, and TM5441 (20 mg·kg−1 oral gavage) was administered daily with the initiation of HFD.Key ResultsTM5441 prevented HFD‐induced body weight gain and systemic insulin resistance. TM5441 normalized HFD‐induced dysregulated JNK and Akt phosphorylation, suggesting that it prevents the insulin resistance of adipocytes. TM5441 also attenuated the macrophage infiltration and increased expression of pro‐inflammatory cytokines, such as inducible nitric oxide synthase, induced by the HFD. In addition, TM5441 prevented the HFD‐induced down‐regulation of genes involved in mitochondrial biogenesis and function, suggesting that it may prevent adipocyte inflammation and dysregulation by maintaining mitochondrial fitness.Conclusion and ImplicationsOur data suggest that TM5441 may become a novel therapeutic agent for obesity and obesity‐related metabolic disorders.